Krystal Biotech Inc (KRYS)
Debt-to-capital ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 946,380 | 778,641 | 522,231 | 593,576 | 292,084 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $946,380K)
= 0.00
The debt-to-capital ratio for Krystal Biotech Inc over the last five years has consistently remained at 0.00. This indicates that the company has not utilized any debt in its capital structure during this period. A debt-to-capital ratio of 0.00 suggests that Krystal Biotech has been relying solely on equity financing to fund its operations, acquisitions, and other investments. While a low debt-to-capital ratio can imply a lower financial risk, it may also limit the company's ability to take advantage of potential tax benefits associated with debt financing. It is important to further evaluate the company's overall financial health and performance metrics to fully understand the implications of its debt-free capital structure.
Peer comparison
Dec 31, 2024